OR WAIT 15 SECS
Philip Ward is ACT's European editor, phone +44 1244 538583, firstname.lastname@example.org
How can you navigate the regulatory triangle safely?
How can you navigate the regulatory triangle safely? Who better to address this question than the respected Brussels-based European Organization for Research and Treatment of Cancer (EORTC).
For anybody seeking regulatory tips and tricks on clinical trials, in vitro diagnostics and data protection, EORTC is staging a workshop in Brussels on 2 December. During the same week, it is organizing two-day meetings about innovation and biomarkers in cancer drug development and markers in cancer diagnostic development.
Among its partners in these events are the European Medicines Agency, the National Cancer Institute, the American Association for Cancer Research, and the American Society of Clinical Oncology.
The EORTC is an independent research organization dedicated to investigator driven clinical trials and translational research. Consisting of both a network and a coordinating scientific and operational infrastructure, it seeks to not only establish ‘state-of-the-art’ treatments but also ensure that new cancer agents are developed and tested efficiently with the aim of minimizing delays between laboratory discovery and their therapeutic benefit for patients.